Summary
Definition
History and exam
Key diagnostic factors
- history of soil exposure in an endemic area
- infection with other parasites
Other diagnostic factors
- abdominal pain
- altered bowel habit
- weight loss
- fever (hyperinfection)
- signs of sepsis (hyperinfection)
- chronic cough
- wheezing
- pruritus or dermatitis
- larva currens
- urticaria
- cutaneous larva migrans
- apparent drug reaction rash (hyperinfection)
- other skin complaints
- symptoms and signs of inflammatory bowel disease
- signs of neurologic manifestations
Risk factors
- soil exposure in endemic region or migrantion from an endemic region
- corticosteroid use (risk of hyperinfection)
- human T-cell lymphotropic virus type-1 (HTLV-1) infection (risk of hyperinfection)
- international travelers
- impaired immunity
- solid-organ transplant recipient
Diagnostic tests
1st tests to order
- stool ova and parasites (O&P) exam
- CBC with differential
- therapeutic trial of ivermectin (in specific situations)
Tests to consider
- sputum O&P exam
- clinical sample (nonstool or sputum) O&P exam
- strongyloides IgG serology
- tissue biopsy
Emerging tests
- polymerase chain reaction (PCR)
- strongyloides IgG4 urine
Treatment algorithm
immigrant from endemic area
able to tolerate oral therapy: not critically ill (nonpregnant)
unable to tolerate oral therapy or critically ill (nonpregnant)
pregnant
poor clinical response or initial treatment not completed
Contributors
Authors
Louis M. Weiss , MD, MPH
Professor, Department of Pathology
Professor, Department of Medicine (Infectious Diseases)
Albert Einstein College of Medicine
Bronx, NY
Disclosures
LMW has received grant funding from the National Institute of Health for research on Toxoplasma gondii and microsporidiosis. LMW receives training grants for infectious diseases at the Albert Einstein College of Medicine, and serves on the board of the Humane Society of Westchester.
Acknowledgements
Dr Louis M. Weiss would like to gratefully acknowledge Dr David R. Boulware, the previous contributor to this topic. DRB declares that he has no competing interests.
Peer reviewers
Elizabeth Barnett, MD
Professor
Department of Pediatrics
Boston Medical Center
Boston University
Boston, MA
Disclosures
EB declares that she is on a speaker's bureau for Merck.
Linda Nield, MD, FAAP
Professor of Pediatrics
West Virginia University School of Medicine
Morgantown, WV
Disclosures
LN declares that she has no competing interests.
Geoff Gill, MA, MSc, MD, FRCP, DTMH
Professor of International Medicine and Honorary Consultant Physician
Liverpool School of Tropical Medicine
Liverpool
UK
Disclosures
GG declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
World Gastroenterology Organisation. WGO practice guideline: management of strongyloidiasis. February 2018 [internet publication].Full text
Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18;(1):CD007745.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Hookworm
- Schistosomiasis
- Filariasis
More DifferentialsGuidelines
- Clinical care of strongyloides
- WGO practice guideline: management of strongyloidiasis
More GuidelinesLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer